Shared on 10 Aug 25

Fair value Decreased 27%

Following a sharp downward revision in expected revenue growth and a substantial rise in the forward P/E ratio, analyst sentiment on FibroGen has weakened, leading to a notable decrease in the consensus price target from $58.77 to $43.00. What's in the News FDA provided positive feedback supporting advancement of roxadustat for anemia in LR-MDS patients with high transfusion burden; Phase 3 trial protocol aligns with FDA recommendations and targets 200 patients.

Read more

0 votesShare

Shared on 01 May 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

0 votesShare

Shared on 24 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

0 votesShare

Shared on 17 Apr 25

Fair value Increased 489%

AnalystConsensusTarget has decreased profit margin from 19.3% to 17.3% and increased future PE multiple from 62.0x to 69.1x.

Read more

0 votesShare